title: [A case of sigmoid colon cancer with a sigmoidovesical fistula treated with preoperative XELOX+bevacizumab therapy and urinary bladder-conserving surgery].
abstract: A 64-year-old man presented with abdominal pain, diarrhea, urinary pain, and frequent urination.He was diagnosed with locally advanced sigmoid colon cancer accompanied by a sigmoidovesical fistula, which was determined to require total cystectomy for curative resection.Expecting tumor shrinkage and conservation of the urinary bladder, we performed loop ileostomy followed by preoperative mFOLFOX6+bevacizumab therapy.After 1 course of administration, the implanted port became infected.Therefore, the regimen was changed to 4 courses of XELOX+bevacizumab therapy.After the treatment, there was no longer any evidence of sigmoidovesical fistula.We performed a urinary bladder-conserving sigmoidectomy and finally achieved pathological curative resection.After adjuvant chemotherapy, no findings suggestive of recurrence were noted during 10 postoperative months.Preoperative XELOX+bevacizumab therapy may be worth considering as a therapeutic option for conserving the urinary bladder in cases of locally advanced colon cancer.
authors.affiliation: Dept. of Surgery, Aomori City Hospital.
authors.forename: Takuya
authors.initials: T
authors.lastname: Miura
authors.forename: Kazunori
authors.initials: K
authors.lastname: Aoki
authors.forename: Akiko
authors.initials: A
authors.lastname: Suto
authors.forename: Toru
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Shojiro Kazunori
authors.initials: SK
authors.lastname: Ikenaga
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kawashima
authors.forename: Itaru
authors.initials: I
authors.lastname: Shibasaki
authors.forename: Masaaki
authors.initials: M
authors.lastname: Endo
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007412:Intestinal Fistula / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010071:Oxaloacetates; D012811:Sigmoid Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D001747:Urinary Bladder Fistula / Q000209:etiology / Q000601:surgery*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil